Literature DB >> 20121741

Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma.

A Cucchetti1, A Vitale, M Del Gaudio, M Ravaioli, G Ercolani, M Cescon, M Zanello, M C Morelli, U Cillo, G L Grazi, A D Pinna.   

Abstract

Primary transplantation offers longer life-expectancy in comparison to hepatic resection (HR) for hepatocellular carcinoma (HCC) followed by salvage transplantation; however, livers not used for primary transplantation can be reallocated to the remaining waiting-list patients, thus, the harm caused to resected patients could be balanced, or outweighed, by the benefit obtained from reallocation of livers originating from HCC patients first being resected. A Markov model was developed to investigate this issue based on literature data or estimated from the United Network for Organ Sharing database. Markov model shows that primary transplantation offers longer life-expectancy in comparison to HR and salvage transplantation if 5-year posttransplant survival remains higher than 60%. The balance between the harm for resected patients and the benefit for the remaining waiting list depends on (a) the proportion of HCC candidates, (b) the percentage shifted to HR and (c) the median expected time-to-transplant. Faced with a low proportion of HCC candidates, the harm caused to resected patients was higher than the benefit that could be obtained for the waiting-list population from re-allocation of extra livers. An increased proportion of HCC candidates and/or an increased median time-to-transplant could lead to a benefit for waiting-list patients that outweighs this harm.

Entities:  

Mesh:

Year:  2010        PMID: 20121741     DOI: 10.1111/j.1600-6143.2009.02984.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  32 in total

Review 1.  [Liver transplantation for hilar cholangiocarcinoma].

Authors:  F Rauchfuss; F Utess; S Schüle; Y Dittmar; H Scheuerlein; U Settmacher
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.

Authors:  Gaya Spolverato; Alessandro Vitale; Aslam Ejaz; Yuhree Kim; Shishir K Maithel; David P Cosgrove; Timothy M Pawlik
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

Review 3.  Liver resection and transplantation in hepatocellular carcinoma.

Authors:  J Belghiti; D Fuks
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 4.  Transplant benefit for patients with hepatocellular carcinoma.

Authors:  Alessandro Vitale; Michael Volk; Umberto Cillo
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

5.  Make the right choice on primary treatments for salvage liver transplantation strategy.

Authors:  Hongyu Li; Bo Li
Journal:  Dig Dis Sci       Date:  2011-12       Impact factor: 3.199

6.  Inappropriate inferences from registry data: Pitfalls of inaccurate data handling?

Authors:  Rahul Kakodkar
Journal:  Indian J Gastroenterol       Date:  2017-03-30

Review 7.  Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence.

Authors:  Shirin Elizabeth Khorsandi; Nigel Heaton
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-06

8.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 9.  Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease.

Authors:  Zenichi Morise
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-16

10.  Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma.

Authors:  Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Alessandro Cucchetti; Valentina Bertuzzo; Gaetano Vetrone; Massimo Del Gaudio; Marco Vivarelli; Antonietta D'Errico-Grigioni; Alessandro Dazzi; Paolo Di Gioia; Augusto Lauro; Antonio Daniele Pinna
Journal:  J Transplant       Date:  2010-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.